相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial
Sara M Tolaney et al.
LANCET ONCOLOGY (2023)
Breast-Conserving Surgery with or without Irradiation in Early Breast Cancer
Ian H. H. Kunkler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2023)
Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab
Coralia Bueno-Muino et al.
JAMA ONCOLOGY (2023)
Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab
Adrienne G. Waks et al.
JAMA ONCOLOGY (2023)
Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial
C. E. Geyer et al.
ANNALS OF ONCOLOGY (2022)
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Effects of capecitabine as part of neo-/adjuvant chemotherapy e A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients
Marion T. van Mackelenbergh et al.
EUROPEAN JOURNAL OF CANCER (2022)
Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update
Fabrice Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
VP6-2022: Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years' follow-up
S. Loibl et al.
ANNALS OF ONCOLOGY (2022)
Impact of the COVID-19 pandemic on breast cancer screening indicators in a Spanish population-based program: a cohort study
Guillermo Bosch et al.
ELIFE (2022)
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial
Arlene Chan et al.
CLINICAL BREAST CANCER (2021)
Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group
Torsten O. Nielsen et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer
Kevin Kalinsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up
Martine Piccart et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age
Martine Piccart et al.
LANCET ONCOLOGY (2021)
Surgical Management of the Axilla in Clinically Node-Positive Breast Cancer Patients Converting to Clinical Node Negativity through Neoadjuvant Chemotherapy: Current Status, Knowledge Gaps, and Rationale for the EUBREAST-03 AXSANA Study
Maggie Banys-Paluchowski et al.
CANCERS (2021)
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
Andrew N. J. Tutt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial
Anna van der Voort et al.
JAMA ONCOLOGY (2021)
The 2019 World Health Organization classification of tumours of the breast
Puay Hoon Tan et al.
HISTOPATHOLOGY (2020)
Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline
Nadine M. Tung et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Novel radiation therapy approaches for breast cancer treatment
Chirag Shah et al.
SEMINARS IN ONCOLOGY (2020)
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial
Adrian Murray Brunt et al.
LANCET (2020)
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
Sandra M. Swain et al.
LANCET ONCOLOGY (2020)
Adjuvant chemotherapy for small, lymph node-negative, triple-negative breast cancer: A single-center study and a meta-analysis of the published literature
Xin An et al.
CANCER (2020)
Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic
Mitch Dowsett et al.
NPJ BREAST CANCER (2020)
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
Stephen R. D. Johnston et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
Elizabeth A. Mittendorf et al.
LANCET (2020)
Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trials
Saroj Niraula et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37298 women with early breast cancer in 26 randomised trials
C. Boddington et al.
LANCET (2019)
St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment
Marija Balic et al.
BREAST CARE (2019)
Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Sara M. Tolaney et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
F. Cardoso et al.
ANNALS OF ONCOLOGY (2019)
Efficacy of extended aromatase inhibitors for hormone-receptor-positive breast cancer: A literature-based meta-analysis of randomized trials
S. P. Corona et al.
BREAST (2019)
Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019
H. J. Burstein et al.
ANNALS OF ONCOLOGY (2019)
Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial
J. M. S. Bartlett et al.
ANNALS OF ONCOLOGY (2019)
Diagnostic Accuracy of Different Surgical Procedures for Axillary Staging After Neoadjuvant Systemic Therapy in Node-positive Breast Cancer
Janine M. Simons et al.
ANNALS OF SURGERY (2019)
Surgical trends in breast cancer: a rise in novel operative treatment options over a 12year analysis
Michael M. Jonczyk et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: a systematic review and meta-analysis
Alessandro Inno et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
G. von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis
F. Poggio et al.
ANNALS OF ONCOLOGY (2018)
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
Antonio C. Wolff et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2018)
PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer
Anne-Vibeke Laenkholm et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Carsten Denkert et al.
LANCET ONCOLOGY (2018)
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
P. A. Francis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
J. A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Trends in Lumpectomy and Oncoplastic Breast-Conserving Surgery in the US, 2011-2016
Chloe Christina Kimball et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
Recommendations for the follow-up care of female breast cancer survivors: a guideline of the Spanish Society of Medical Oncology (SEOM), Spanish Society of General Medicine (SEMERGEN), Spanish Society for Family and Community Medicine (SEMFYC), Spanish Society for General and Family Physicians (SEMG), Spanish Society of Obstetrics and Gynecology (SEGO), Spanish Society of Radiation Oncology (SEOR), Spanish Society of Senology and Breast Pathology (SESPM), and Spanish Society of Cardiology (SEC)
A. Barnadas et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2018)
Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression (vol 25, pg 1551, 2014)
U. Nitz et al.
ANNALS OF ONCOLOGY (2017)
Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis The ACOSOG Z0011 (Alliance) Randomized Clinical Trial
Armando E. Giuliano et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline
Sukhbinder Dhesy-Thind et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
David Cameron et al.
LANCET (2017)
Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial
Marloes G. M. Derks et al.
LANCET ONCOLOGY (2017)
Clinical validity and Utility of Tumor-infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions
Lironne Wein et al.
FRONTIERS IN ONCOLOGY (2017)
A Novel Breast Cancer Index for Prediction of Distant Recurrence in HR+ Early-Stage Breast Cancer with One to Three Positive Nodes
Yi Zhang et al.
CLINICAL CANCER RESEARCH (2017)
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
G. Curigliano et al.
ANNALS OF ONCOLOGY (2017)
Breast Cancer-Major Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual
Armando E. Giuliano et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay
Aleix Prat et al.
CLINICAL CANCER RESEARCH (2016)
Operative and Oncologic Outcomes in 9861 Patients with Operable Breast Cancer: Single-Institution Analysis of Breast Conservation with Oncoplastic Reconstruction
Stacey A. Carter et al.
ANNALS OF SURGICAL ONCOLOGY (2016)
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
F. Cardoso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Complete blood counts, liver function tests, and chest x-rays as routine screening in early-stage breast cancer: value added or just cost?
Raphael J. Louie et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
Regional Nodal Irradiation in Early-Stage Breast Cancer
Timothy J. Whelan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
J. A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Disparities in the Use of Breast-Conserving Therapy Among Patients With Early-Stage Breast Cancer
Meeghan Lautner et al.
JAMA SURGERY (2015)
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone
M. Gnant et al.
ANNALS OF ONCOLOGY (2014)
Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831
Edith A. Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar et al.
LANCET (2014)
Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial
Mila Donker et al.
LANCET ONCOLOGY (2014)
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)
A. Schneeweiss et al.
ANNALS OF ONCOLOGY (2013)
Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients
Holm Eggemann et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2-breast cancer patients
P. Dubsky et al.
BRITISH JOURNAL OF CANCER (2013)
An update on male breast cancer and future directions for research and treatment
Sousa Berta et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2013)
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
Christina Davies et al.
LANCET (2013)
Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population
Dennis C. Sgroi et al.
LANCET ONCOLOGY (2013)
Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study
E. Alba et al.
ANNALS OF ONCOLOGY (2012)
18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques
Bas B. Koolen et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
K. Albain et al.
LANCET (2012)
Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial
Norikazu Masuda et al.
LANCET ONCOLOGY (2012)
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Luca Gianni et al.
LANCET ONCOLOGY (2012)
FDG-PET/CT in the staging of local/regional metastases in breast cancer
Ian J. Robertson et al.
BREAST (2011)
Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor-Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype-ACOSOG Z1031
Matthew J. Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Dennis Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Quality and Strength of Evidence of the Infectious Diseases Society of America Clinical Practice Guidelines
Abdur Rahman Khan et al.
CLINICAL INFECTIOUS DISEASES (2010)
Magnetic resonance imaging of the breast: Recommendations from the EUSOMA working group
Francesco Sardanelli et al.
EUROPEAN JOURNAL OF CANCER (2010)
Multidisciplinary Meeting on Male Breast Cancer: Summary and Research Recommendations
Larissa A. Korde et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
Kathy S. Albain et al.
LANCET ONCOLOGY (2010)
Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735
Stephen Jones et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase III Trial Evaluating the Addition of Paclitaxel to Doxorubicin Followed by Cyclophosphamide, Methotrexate, and Fluorouracil, As Adjuvant or Primary Systemic Therapy: European Cooperative Trial in Operable Breast Cancer
Luca Gianni et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer
Henning Mouridsen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition - summary document
N. Perry et al.
ANNALS OF ONCOLOGY (2008)
Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer
Caroline Lohrisch et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
Soonmyung Paik et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial
R Jakesz et al.
LANCET (2005)
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Preliminary results of the Italian Tamoxifen Anastrozole trial
F Boccardo et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial
IE Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
A Howell et al.
LANCET (2005)
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer
RC Coombes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)